Health-Related Quality of Life in Chronic Pain Treated With Tapentadol Versus Oxycodone/Naloxone and Its Determinants: A Real-World, Single-Center Retrospective Cohort Study in Spain

Objectives: A substantial proportion of patients with chronic noncancer pain (CNCP) are treated with tapentadol (TAP) or oxycodone/naloxone (OXN) to improve their perceived physical and mental health over time. Methods: A cross-sectional study was conducted in 135 CNCP outpatients with usual prescribing (TAP: n = 58, OXN: n = 77) at a tertiary-care Spanish Hospital to compare health-related quality-of-life (HRQoL) records. Health utility was derived from the EQ-5D-3L. Regression models were performed to search for other HRQoL determinants. Pain intensity, relief, analgesic prescription, adverse events, inpatient stays, emergency department visits, and change to painkiller prescriptions were registered from electronic records. Results: Health utility (0.43 6 0.24 scores, from-0.654 to 1) was similar for both opioids, although TAP showed a signi ficantly low daily opioid dose requirement, neuromodulators use, and constipation side effect compared with OXN. After multivariable adjustment, the signi ficant predictors of impaired HRQoL were pain intensity ( 5 =-0.227, 95% CI-0-035 to-0.0 05), number of adverse events ( 5 =-0.201, 95% CI-0.024 to-0.004), and opioid daily dose ( 5 =-0.175, 95% CI-0.097 to-0.012). Male sex ( 5 = -0.044) and pain relief ( 5 = 0.158) should be taken into account for future studies. Conclusions: HRQoL was similar for TAP and OXN in real-world patients with CNCP, albeit with a TAP opioid-sparing effect. More work is needed to explore HRQoL determinants in relation to long-term opioid use in CNCP.